Saturday, August 19, 2017 3:56:29 PM
A Prescient Article From 3 Years Ago !
THE COMPANY’S Good Manufacturing Practice- certified manufacturing facilities efficiently produce commercial quantities of homogeneous PLX cells suitable for clinical studies, making it the only company so far to manufacture large quantities of placenta- based cell products using a “bioreactor.”
These shiny glass-and-metal containers, invented by Pluristem, create a three-dimensional micro-environment for the controlled, large-scale growth of cells at a fraction of the cost of traditionally expanding cells using culture dishes. Their processes have approval from the US Food and Drug Administration (FDA) and regulatory authorities in Israel, Germany, Australia, Singapore and elsewhere.
“We believe that cell therapy will be significant in the future. A number of major companies such as Genentech, Amgen and Genzyme were established decades ago.
Every biopharma company is working in the field of biological therapy,” said Aberman. “A quarter of a century ago, everybody thought embryonic stem cells produced from fetuses were the next big thing. But at Pluristem, we believe in adult stem cells from placentas to create drugs adapted to the patient himself.”
“Embryonic stem cells produce factors such as white cells or red cells for a certain specific condition. But we use a different technique, taking cells from placentas and producing universal therapeutic cells. We want to be the world’s leading company in developing and manufacturing cell therapies. We had offers from big firms that wanted to buy us, but we refused,” added Aberman, waving a little bottle of pink liquid, containing PLX cells. They are deep-frozen and sent around the world for testing and eventual use, and defrosted using a patented warmer developed at Pluristem that does not cause them any harm.
http://www.jpost.com/Israel-News/Health/Biotech-mission-To-help-the-body-repair-itself-380495
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM